Compare OPRX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | PRQR |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.5M | 250.7M |
| IPO Year | N/A | 2014 |
| Metric | OPRX | PRQR |
|---|---|---|
| Price | $13.36 | $2.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $14.83 | $8.14 |
| AVG Volume (30 Days) | 221.9K | ★ 540.5K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $109,506,000.00 | $18,859,556.00 |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $7,312.30 | ★ N/A |
| Revenue Growth | ★ 24.18 | N/A |
| 52 Week Low | $3.99 | $1.07 |
| 52 Week High | $22.25 | $3.46 |
| Indicator | OPRX | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 53.75 |
| Support Level | $13.14 | $2.15 |
| Resistance Level | $14.95 | $2.42 |
| Average True Range (ATR) | 0.66 | 0.19 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 14.05 | 79.70 |
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.